IP Library › Granted Patent US 10,683,280
Granted Patent B2
US 10,683,280 · App. 16/256,987 · Granted Jun 16, 2020

Chemokine receptor modulators and uses thereof

Inventors: Jeffrey J. Jackson (San Bruno, CA); John Michael Ketcham (San Mateo, CA); Akinori Okano (San Mateo, CA); Maureen Kay Reilly (San Francisco, CA); Omar Robles-Resendiz (Redwood City, CA); Jacob Bradley Schwarz (San Ramon, CA); Parcharee Tivitmahaisoon (San Francisco, CA); David Juergen Wustrow (Los Gatos, CA); Ashkaan Younai (Daly City, CA); Mikhail Zibinsky (Redwood City, CA)
Assignee: RAPT THERAPEUTICS, INC.
C07D401/14A61P11/06A61P17/00A61P29/00A61P35/00C07D495/04
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,683,280
App. No.
16/256,987
Granted
Jun 16, 2020
Kind
B2
Abstract

Disclosed herein, inter alia, are compounds and methods of use thereof for the modulation of certain chemokine receptor activity.

Claims (43)

1. A compound having the following structure:

or a pharmaceutically acceptable salt thereof.

2. A pharmaceutical composition comprising a pharmaceutically acceptable excipient and a compound of claim 1 , or a pharmaceutically acceptable salt thereof.

3. A compound having the formula:

or a pharmaceutically acceptable salt thereof.

4. A compound having the formula:

or a pharmaceutically acceptable salt thereof.

5. A compound having the formula:

or a pharmaceutically acceptable salt thereof.

6. A compound having the formula:

or a pharmaceutically acceptable salt thereof.

7. A compound having the formula:

or a pharmaceutically acceptable salt thereof.

8. A compound having the formula:

or a pharmaceutically acceptable salt thereof.

9. A compound having the formula:

or a pharmaceutically acceptable salt thereof.

10. A compound having the formula:

or a pharmaceutically acceptable salt thereof.

11. A compound having the formula:

or a pharmaceutically acceptable salt thereof.

12. A compound having the formula:

or a pharmaceutically acceptable salt thereof.

13. A compound having the formula:

or a pharmaceutically acceptable salt thereof.

14. A compound having the formula:

or a pharmaceutically acceptable salt thereof.

15. A compound having the formula:

or a pharmaceutically acceptable salt thereof.

16. The compound of claim 15 having the formula:

or a pharmaceutically acceptable salt thereof.

17. A compound having the formula:

or a pharmaceutically acceptable salt thereof.

18. The compound of claim 17 having the formula:

or a pharmaceutically acceptable salt thereof.

19. A compound having the formula:

or a pharmaceutically acceptable salt thereof.

20. The compound of claim 19 having the formula:

or a pharmaceutically acceptable salt thereof.

21. A compound having the formula:

or a pharmaceutically acceptable salt thereof.

22. The compound of claim 21 having the formula:

or a pharmaceutically acceptable salt thereof.

Assignments (2)
CHANGE OF NAME Recorded Aug 1, 2019
From: FLX BIO, INC.
To: RAPT THERAPEUTICS, INC.
Reel/Frame 049934/0074 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 12, 2019
From: JACKSON, JEFFREY J.; KETCHAM, JOHN MICHAEL; OKANO, AKINORI; REILLY, MAUREEN KAY; ROBLES-RESENDIZ, OMAR; SCHWARZ, JACOB BRADLEY; TIVITMAHAISOON, PARCHAREE; WUSTROW, DAVID JUERGEN; YOUNAI, ASHKAAN; ZIBINSKY, MIKHAIL
To: FLX BIO, INC.
Reel/Frame 049745/0001 →
Continuity (4)
Provisional Application 62784161 · Dec 21, 2018
Provisional Application 62772027 · Nov 27, 2018
Provisional Application 62622771 · Jan 26, 2018
Related Publication 20190233397A1 · Aug 1, 2019
Cited By (2)
US 12,240,837 US 12,428,393